Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Taking a Break https://t.co/QgH851GMZX #Science #Business
    about 2 days ago
  • Total venture capital funding in the U.S. for first six months of 2019 reached levels not seen since the year 2000,… https://t.co/cGSC6j1Xl8
    about 2 days ago
  • New post on Science and Enterprise: Infographic – U.S. Venture Funds Near 20-Year Highs https://t.co/mIkraoGRAH #Science #Business
    about 2 days ago
  • A set of computational tools developed at Purdue University enables public safety agencies to monitor potentially c… https://t.co/NHSLm9YBBG
    about 3 days ago
  • New post on Science and Enterprise: A.I. Helps Visualize Emergency Social Media Data https://t.co/E94lXHnPsa #Science #Business
    about 3 days ago

Please share Science & Enterprise

Infographic – U.S. Venture Funds Near 20-Year Highs

Venture investment chart

Total venture capital funding in the U.S. for first six months of 2019 reached levels not seen since the year 2000, the waning days of the dot-com era. . . . → Read More: Infographic – U.S. Venture Funds Near 20-Year Highs

Genentech, Biotech Partner on Multiple Sclerosis

Neurons illustration

A company designing treatments to restore the protective coating on nerve cells damaged by multiple sclerosis is collaborating with biotechnology enterprise Genentech. . . . → Read More: Genentech, Biotech Partner on Multiple Sclerosis

Infographic – Top Tech Acquisition Timeline

Top tech industry acquisitions

The world’s five leading technology enterprises are acquiring more companies and with more money in recent years than before. . . . → Read More: Infographic – Top Tech Acquisition Timeline

Immunotherapy Biotech Gains $325M in Venture Funds

Investment graphic

A biotechnology enterprise developing personalized treatments for cancer and infectious diseases is raising $325 million in its second venture funding round. . . . → Read More: Immunotherapy Biotech Gains $325M in Venture Funds

Stem Cell Start-Up Raises $250M in Venture Funds

T-cell lymphocyte

A company begun last year to create cancer therapies from banked, off-the-shelf stem cells is raising $250 million in its first round of venture financing. . . . → Read More: Stem Cell Start-Up Raises $250M in Venture Funds

Two Biotechs Each Issue $300M+ IPOs

NASDAQ share price display

Two biotechnology enterprises in the U.S. issued their initial public stock offerings yesterday, with each company raising at least $300 million in their transactions. . . . → Read More: Two Biotechs Each Issue $300M+ IPOs

A.I. Chip Start-Up Raises $23M in Early Funds

A start-up enterprise is developing computer chips designed to run artificial intelligence, or A.I., applications but with an architecture it says can avoid memory logjams. . . . → Read More: A.I. Chip Start-Up Raises $23M in Early Funds

Company Launches Attacking Cancer Proteins, Lands $67M

Cancer magnified

A new enterprise is starting-up to develop treatments that target cancer-causing proteins considered unreachable with current therapies. . . . → Read More: Company Launches Attacking Cancer Proteins, Lands $67M

Liquid Biopsy Screening Start-Up Launches, Gains $110M

Blood sample tubes

A new enterprise is starting up, developing early-stage cancer screening with a single blood test, based on research at Johns Hopkins University. . . . → Read More: Liquid Biopsy Screening Start-Up Launches, Gains $110M

Viral Disease Biotech Joins ElevateBio, Gains $120M

T-cells illustration

A biotechnology company developing immunotherapies for viral diseases is joining the ElevateBio consortium providing manufacturing for cell and gene therapies. . . . → Read More: Viral Disease Biotech Joins ElevateBio, Gains $120M